Answers are grounded in this paper and cite their sources.
Prostate cancer was a major cause of death during the first decade after RT for patients with clinically localized but high-risk disease, and the cause of death for patients with a short PSA DT after RT was nearly always prostate cancer. These data provide evidence to propose the hypothesis that a short posttreatment PSA DT may serve as a possible surrogate for PCSD. Prospective validation is needed.
No takes yet. Share an insight, caveat, or question.
D’Amico et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: